Financhill
Sell
35

TBPH Quote, Financials, Valuation and Earnings

Last price:
$11.31
Seasonality move :
-3.18%
Day range:
$11.25 - $11.41
52-week range:
$7.44 - $11.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.52x
P/B ratio:
3.40x
Volume:
179.1K
Avg. volume:
296.2K
1-year change:
21.11%
Market cap:
$565M
Revenue:
$64.4M
EPS (TTM):
-$1.18

Analysts' Opinion

  • Consensus Rating
    Theravance Biopharma has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $17.20, Theravance Biopharma has an estimated upside of 52.21% from its current price of $11.30.
  • Price Target Downside
    According to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $11.30.

Fair Value

  • According to the consensus of 4 analysts, Theravance Biopharma has 52.21% upside to fair value with a price target of $17.20 per share.

TBPH vs. S&P 500

  • Over the past 5 trading days, Theravance Biopharma has overperformed the S&P 500 by 1.66% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Theravance Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Theravance Biopharma has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Theravance Biopharma reported revenues of $15.4M.

Earnings Growth

  • Theravance Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Theravance Biopharma reported earnings per share of -$0.27.
Enterprise value:
434.2M
EV / Invested capital:
--
Price / LTM sales:
8.52x
EV / EBIT:
--
EV / Revenue:
6.65x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
13.35x
Price / Operating cash flow:
17.09x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-16.32%
Net Income Margin (TTM):
-89.38%
Return On Equity:
-31.51%
Return On Invested Capital:
-31.51%
Operating Margin:
-93.8%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $48.6M $61.5M $65.3M $14.5M $15.4M
Gross Profit -- -- -- -- --
Operating Income -$74.6M -$41.2M -$45.7M -$11.2M -$14.4M
EBITDA -$64.1M -$30.3M -$42.3M -$8.6M -$12.4M
Diluted EPS $11.53 -$0.86 -$1.18 -$0.24 -$0.27
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $293.1M $204.6M $261.3M $124.3M $150.3M
Total Assets $375.1M $355.4M $538.6M $371.3M $343.6M
Current Liabilities $86.5M $44.2M $26.2M $21.7M $31.5M
Total Liabilities $748.3M $706.8M $168M $166.4M $177.6M
Total Equity -$373.2M -$351.5M $370.6M $204.9M $166M
Total Debt $614.1M $621.5M -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$172.1M -$16.8M $32.5M -$1M $43M
Cash From Investing $1.1B $27.4M $25.9M $17M $30.6M
Cash From Financing -$813.6M -$144.4M -$1.6M -$1.7M -$854K
Free Cash Flow -$173.4M -$18.4M $32.5M -$1.1M $43M
TBPH
Sector
Market Cap
$565M
$33.5M
Price % of 52-Week High
95.6%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
0.48%
-0.97%
1-Year Price Total Return
21.12%
-33.61%
Beta (5-Year)
-0.018
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $11.25
200-day SMA
Buy
Level $9.40
Bollinger Bands (100)
Buy
Level 8.87 - 10.59
Chaikin Money Flow
Buy
Level 25.3K
20-day SMA
Buy
Level $10.93
Relative Strength Index (RSI14)
Buy
Level 60.18
ADX Line
Buy
Level 25.65
Williams %R
Neutral
Level -30.5221
50-day SMA
Buy
Level $10.29
MACD (12, 26)
Buy
Level 2.53
25-day Aroon Oscillator
Buy
Level 56
On Balance Volume
Sell
Level -316.7K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-2.0261)
Sell
CA Score (Annual)
Level (-0.7847)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.3782)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Stock Forecast FAQ

In the current month, TBPH has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TBPH average analyst price target in the past 3 months is $17.20.

  • Where Will Theravance Biopharma Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Theravance Biopharma share price will rise to $17.20 per share over the next 12 months.

  • What Do Analysts Say About Theravance Biopharma?

    Analysts are divided on their view about Theravance Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Theravance Biopharma is a Sell and believe this share price will drop from its current level to $10.00.

  • What Is Theravance Biopharma's Price Target?

    The price target for Theravance Biopharma over the next 1-year time period is forecast to be $17.20 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is TBPH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Theravance Biopharma is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of TBPH?

    You can purchase shares of Theravance Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Theravance Biopharma shares.

  • What Is The Theravance Biopharma Share Price Today?

    Theravance Biopharma was last trading at $11.31 per share. This represents the most recent stock quote for Theravance Biopharma. Yesterday, Theravance Biopharma closed at $11.30 per share.

  • How To Buy Theravance Biopharma Stock Online?

    In order to purchase Theravance Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock